Antimicrobial pharmacokinetics in patients with cystic fibrosis, lung and bone marrow transplant.

Infections are a common complication and cause of mortality in transplant and cystic fibrosis patients. Such infections are potentially treatable if appropriate antimicrobials are administered early.

Lung transplant, bone marrow transplant and cystic fibrosis patients bear many similarities to ICU patients with poor outcomes associated with suboptimal antimicrobial dosing.

This population of patients currently have only sparse pharmacokinetic data yet are routinely treated with antimicrobial doses validated in healthy volunteers. A much better characterisation of antimicrobial pharmacokinetics in these patients is required.

Relevant Publications

Whitmore, Timothy J., Cheng, Vesa, Rawlins, Matthew D., Morgan, David, Chang, Tim, O'Halloran, Sean, Dyer, John R., Boan, Peter and Roberts, Jason A. (2022). Pharmacokinetics of valganciclovir and voriconazole during prolonged intermittent renal replacement therapy in a lung transplant recipient. Transplant Infectious Disease, 24 (2) e13818, e13818. doi: 10.1111/tid.13818

Burke, Andrew, Smith, Daniel, Coulter, Chris, Bell, Scott C., Thomson, Rachel and Roberts, Jason A. (2021). Clinical pharmacokinetic and pharmacodynamic considerations in the drug treatment of non-tuberculous mycobacteria in cystic fibrosis. Clinical Pharmacokinetics, 60 (9), 1081-1102. doi: 10.1007/s40262-021-01010-4

Byrne, C., Parton, T., Mcwhinney, B., Fennell, J., O'Byrne, P., Deasy, E., . . . Roberts, J. (2017). Population pharmacokinetics of total and unbound teicoplanin concentrations and dosing simulations in patients with haematological malignancy. The Journal of Antimicrobial Chemotherapy, The Journal of antimicrobial chemotherapy, 18 December 2017. DOI: 10.1093/jac/dkx473